Compounds · Other compounds · continued

Compounds this community declines to help with, and why posts 61–88

Compounds › Other compounds research use only needs a source mislabelling custom synthesis Solved Wiki

This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.

buffer_sheetTL3Regular4 Oct 2025#61

b.jankowiak, post #14: Several compounds discussed here have no published human pharmacokinetics at all. That means half-life claims in circulation were derived from an animal model or from nothing. Adding this to the thread rather than to the wiki, because I am not confident enough for the wiki. Go to post

Dose conversions between related compounds in this subcategory are made far too casually. Structural similarity does not imply potency similarity and frequently does not imply the same receptor profile.

I would rather post the uncertainty than round it away.

6 likes in reply to #14 10mo

b.wikstromTL24 Oct 2025#62

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

That is what I would do. It may not be what is correct.

1 like 10mo

bench_entryTL3Regular5 Oct 2025#63

Second this, and I would have said it less carefully.

31 likes 10mo

p.dialloTL25 Oct 2025#64

Several compounds discussed here have no published human pharmacokinetics at all. That means half-life claims in circulation were derived from an animal model or from nothing.

16 likes 10mo

b.jankowiakTL3Regular5 Oct 2025#65

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

3 likes 10mo

j.falkTL25 Oct 2025#66

Collapsed as off-topic by two members at trust level 3 or above

AOD-9604 is a fragment of human growth hormone and has been discussed as a potential weight-loss agent based on theoretical mechanism. The fragment hypothesis — that the fragment retains a specific property of the intact hormone — is not settled for this compound.

y.mensahTL3Wiki editor5 Oct 2025 · edited#67

Post #64 describes the usual case. This is about the unusual one.

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

The claim is narrower than it sounds, and deliberately so.

23 likes 10mo

h.espinozaTL25 Oct 2025#68

Ziegler, post #31: Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here. Take it as a starting point and not as a specification. Go to post

Adding the measurement that post #67 says would settle it.

This subcategory exists because some people will research compounds outside the main groups discussed here. The standard of evidence and honesty about its limits applies to everything discussed, not just to approved drugs.

11 likes in reply to #31 10mo

MJayawardenaTL3Regular6 Oct 2025#69

Post #67 put the caveat in the right place and I want to underline it.

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

For what it is worth, the same held on the two occasions I checked.

15 likes 10mo

c.marchettiTL26 Oct 2025#70

Building on post #67 rather than restating it.

Storage guidance for the less common material is usually copied from the incretin guidance and may not apply. Where the supplier has its own stability statement, that is the one to use.

6 likes 10mo

ppm_errorTL3Analytical chemist6 Oct 2025#71

blank_injection, post #26: Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here. Go to post

Right — I had this wrong and I am glad to have read it before it mattered.

11 likes in reply to #26 10mo

a.pereiraTL26 Oct 2025#72

Post #68 put the caveat in the right place and I want to underline it.

Anything in this subcategory with a published trial behind it should be discussed separately from anything without one. Mixing them produces a discussion where the confident claims come from the compounds with the least evidence.

24 likes 10mo

forest_plotTL3Evidence synthesis6 Oct 2025#73

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

I checked the source rather than the summary, and they differ.

0 likes 10mo

n.cardosoTL26 Oct 2025#74

Why catalogue breadth is not evidence of anything: a supplier listing 500 compounds does not make the 450 untested ones likely to work. It makes them untested compounds with supplier pages.

I would put a moderate confidence on that and no more.

3 likes 10mo

j.mwangiTL4 Moderator7 Oct 2025#75

y.asante, post #19: Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here. This is the sort of thing that ought to be settled and apparently is not. Go to post

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

The reasoning is more useful than the number, which is why I have shown it.

16 likes in reply to #19 10mo

d.eriksenTL27 Oct 2025#76

Compounds this community declines to help with, and why: there are specifics in the guidelines and they are not arbitrary. They exist because of failure modes that have happened in real people, not because of prudishness.

That is the honest state of it as of this week.

32 likes 10mo

m.strand_rphTL3Pharmacist7 Oct 2025#77

The arithmetic in post #74 is right; the assumption feeding it is the part to check.

PT-141 was developed from the same family with a different receptor profile, and it has a considerably better documented human evidence base than most compounds discussed in this subcategory.

1 like 10mo

h.bakkerTL27 Oct 2025#78

Collapsed as off-topic by two members at trust level 3 or above

Distinguishing marketed research compounds from true chemical synthesis: some online suppliers sell compounds that are genuinely novel and difficult to obtain elsewhere. Others repackage standard compounds. Verifying what you are buying requires careful documentation review.

Anyone with a larger sample, please post it.

a.kowalczykTL2Regular7 Oct 2025#79

endo_fellow_rk, post #45: I had written a reply contradicting post #41 and deleted it. Here is what survived. Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here. Go to post

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

4 likes in reply to #45 10mo

m.almeidaTL27 Oct 2025#80

bench_entry, post #63: Second this, and I would have said it less carefully. Go to post

That reframing is the whole thing. The facts I already had.

12 likes in reply to #63 10mo

i.coelhoTL28 Oct 2025#81

Collapsed as off-topic by two members at trust level 3 or above

Noted, and thank you for writing it out rather than summarising it.

d.petrescuTL28 Oct 2025#82

That is the version I would defend. It is not the version I started with.

9 likes 10mo

j.baptistaTL28 Oct 2025#83

Coming back to post #82, because the follow-up matters more than the original answer.

Why catalogue breadth is not evidence of anything: a supplier listing 500 compounds does not make the 450 untested ones likely to work. It makes them untested compounds with supplier pages.

2 likes 10mo

c.dahlbergTL28 Oct 2025#84

Birkeland, post #12: Coming back to post #10, because the follow-up matters more than the original answer. Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here. Go to post

Post #82 is right about the mechanism and I think understates the practical bit.

Research use only, not approved for human use, and in this subcategory the compounds vary enormously in how much is known about them. It is worth establishing which end of that range a specific compound sits at before anything else.

0 likes in reply to #12 10mo

l.wikstromTL28 Oct 2025#85

MJayawardena, post #69: Post #67 put the caveat in the right place and I want to underline it. Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here. For what it is worth, the same held on the two occasions I checked. Go to post

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

15 likes in reply to #69 10mo

v.nascimentoTL28 Oct 2025#86

How to research a compound with no human data: mechanistic plausibility is one input. Preclinical data is another. The honest position is that you are reasoning from theory, not from evidence, and the track record of such reasoning is unimpressive when tested against actual outcomes.

A qualification I should have led with rather than closed on.

6 likes 10mo

KLindqvistTL4 Moderator8 Oct 2025 · edited#87

The tanning compounds carry a specific practical point that is not pharmacological: any change to a pigmented lesion is a reason to see a clinician, and that is not a matter of opinion or of dose.

The rule of thumb is fine; the edge cases are where it earns its keep.

1 like 10mo

f.kimaniTL29 Oct 2025#88

Makinen, post #3: Compounds this community declines to help with, and why: there are specifics in the guidelines and they are not arbitrary. They exist because of failure modes that have happened in real people, not because of prudishness. Go to post

Post #85 answers the question as asked. The question underneath it is different.

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

I would treat the number as indicative rather than as a measurement.

0 likes in reply to #3 10mo

Topic	Participants	Replies	Views	Activity
Second pass at: How to research a compound with no human data without deceiving yourself Compounds › Other compounds research use only custom synthesis needs a source mislabelling Second pass at: How to research a compound with no human data without deceiving yourself Writing it up because I had to work it out twice and would rather nobody else did. The question about research a…	+64	71	2.5k	13mo
How to research a compound with no human data without deceiving yourself Compounds › Other compounds needs a source mislabelling custom synthesis research use only Solved Asking directly, because I could not find a straight answer: How to research a compound with no human data without deceiving yourself Question about what the published evidence for this compound actually…	+107	119	11k	12mo
Research-use-only status: what it means legally and practically Compounds › Other compounds research use only custom synthesis needs a source mislabelling Research-use-only status: what it means legally and practically Writing it up because I had to work it out twice and would rather nobody else did. Asking about research-use-only status directly, because I…	+72	81	44k	1d
Coming back to: Reading a supplier's product description as a marketing document Compounds › Other compounds needs a source custom synthesis research use only mislabelling Reading a supplier's product description as a marketing document Writing it up because I had to work it out twice and would rather nobody else did. Documentation question rather than a pharmacological one,…	+35	39	688	5mo
AOD-9604 and the fragment hypothesis, revisited — does this still hold? Compounds › Other compounds research use only needs a source mislabelling Solved The question in the title: AOD-9604 and the fragment hypothesis, revisited — does this still hold? I will give what I have already checked below so nobody repeats it. What changes if the standard account of…	+7	11	31k	19h

Topic	Participants	Replies	Views	Activity
Coming back to: Payment mechanics and the recovery options that do not exist Sourcing › Payments research use only payments documentation quality Under review On the subject in the title: Payment mechanics and the recovery options that do not exist Working notes rather than a conclusion. A payments question, with the mechanics separated from the money. What I would…	+7	11	2.6k	7mo
Revisiting: Patterns that reliably precede a problem, documented Sourcing › Red flags underdosing moderation mislabelling documentation quality Posting this under the heading it deserves: Revisiting: Patterns that reliably precede a problem, documented Everything below is what sits behind that. Patterns, from the point of view of someone who has read…	+16	20	36k	2mo
Common supplements people ask about, assessed one at a time — a second dataset Practice › Interactions delayed gastric emptying insulin needs a source Posting this under the heading it deserves: Common supplements people ask about, assessed one at a time — a second dataset Everything below is what sits behind that. A follow-up question about Common…	+97	104	15k	3mo
Revisiting: How this community labels and discusses unrefereed work Evidence › Preprints needs a source risk of bias preprint effect size Solved Revisiting: How this community labels and discusses unrefereed work Writing it up because I had to work it out twice and would rather nobody else did. Reading an unrefereed manuscript properly, and asking…	+31	35	7k	1d
Labelling requirements for research chemicals — the long version Sourcing › Regulatory MHRA research use only compounding personal import Posting this under the heading it deserves: Labelling requirements for research chemicals — the long version Everything below is what sits behind that. A narrow question about Labelling requirements for…		2	1.8k	2mo

Compounds this community declines to help with, and why posts 61–88

Suggested topics

Related topics — sharing the tags research use only, needs a source, mislabelling